The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | T-cell evolution in AML and its impact on the efficacy of bispecific antibodies
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses the importance of better understanding the mode of action of bispecific antibodies and CAR-T cells in hematological malignancies, drawing focus on one study that investigated T-cell evolution in acute myeloid leukemia (AML) patients. Dr Subklewe briefly explains some findings from this study, which analyzed numerous factors and found that T-cell function decreases throughout the progression of this disease, and how this may impact the efficacy of bispecific antibodies in the treatment of AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
